WO1998036730A3 - Compositions de traitement de l'acne rosacee - Google Patents

Compositions de traitement de l'acne rosacee Download PDF

Info

Publication number
WO1998036730A3
WO1998036730A3 PCT/EP1998/000991 EP9800991W WO9836730A3 WO 1998036730 A3 WO1998036730 A3 WO 1998036730A3 EP 9800991 W EP9800991 W EP 9800991W WO 9836730 A3 WO9836730 A3 WO 9836730A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
acne rosacea
treating acne
rosacea
prevention
Prior art date
Application number
PCT/EP1998/000991
Other languages
German (de)
English (en)
Other versions
WO1998036730A2 (fr
Inventor
Walter Diembeck
Udo Hoppe
Birgit Salzer
Gerhard Sauermann
Volker Steinkraus
Original Assignee
Beiersdorf Ag
Walter Diembeck
Udo Hoppe
Birgit Salzer
Gerhard Sauermann
Volker Steinkraus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19711565A external-priority patent/DE19711565A1/de
Application filed by Beiersdorf Ag, Walter Diembeck, Udo Hoppe, Birgit Salzer, Gerhard Sauermann, Volker Steinkraus filed Critical Beiersdorf Ag
Priority to JP53626998A priority Critical patent/JP2001512471A/ja
Priority to EP98913571A priority patent/EP0969790A2/fr
Publication of WO1998036730A2 publication Critical patent/WO1998036730A2/fr
Publication of WO1998036730A3 publication Critical patent/WO1998036730A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation, notamment l'utilisation topique, d'un ou plusieurs composés sélectionnés dans le groupe des inhibiteurs de la NO-synthase et de leurs dérivés pour la prophylaxie et/ou le traitement de l'acné rosacée et de la couperose.
PCT/EP1998/000991 1997-02-21 1998-02-20 Compositions de traitement de l'acne rosacee WO1998036730A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP53626998A JP2001512471A (ja) 1997-02-21 1998-02-20 しゅさの処置のための調製物
EP98913571A EP0969790A2 (fr) 1997-02-21 1998-02-20 Compositions de traitement de l'acne rosacee

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19706581 1997-02-21
DE19711565A DE19711565A1 (de) 1997-02-21 1997-03-20 Zubereitungen für die Behandlung von Rosacea
DE19706581.3 1997-03-20
DE19711565.9 1997-03-20

Publications (2)

Publication Number Publication Date
WO1998036730A2 WO1998036730A2 (fr) 1998-08-27
WO1998036730A3 true WO1998036730A3 (fr) 1998-10-22

Family

ID=26034114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/000991 WO1998036730A2 (fr) 1997-02-21 1998-02-20 Compositions de traitement de l'acne rosacee

Country Status (3)

Country Link
EP (1) EP0969790A2 (fr)
JP (1) JP2001512471A (fr)
WO (1) WO1998036730A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19918750A1 (de) * 1999-04-24 2000-10-26 Beiersdorf Ag Wirkstoffe, kosmetische und dermatologische Zubereitungen für die Verbesserung der Barrierefunktion
FR2794974B1 (fr) * 1999-06-16 2001-08-17 Exsymol Sa Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique
FR2808189B1 (fr) * 2000-04-28 2004-03-05 Oreal Lipochroman-6 comme inhibiteur de no-synthase et utilisations
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
JP4814567B2 (ja) * 2004-09-02 2011-11-16 コスモ石油株式会社 健康機能向上剤
JP4814501B2 (ja) * 2004-09-02 2011-11-16 コスモ石油株式会社 抗酸化機能向上剤
JP4814568B2 (ja) * 2004-09-02 2011-11-16 コスモ石油株式会社 免疫機能向上剤
AU2005278649B8 (en) 2004-09-02 2010-07-22 Cosmo Ala Co., Ltd. Constitutional function-improving agents
EP2653160B1 (fr) * 2006-10-12 2017-09-27 Topaz Pharmaceuticals Inc. Formulations topiques d'ivermectine et procédés d'élimination et prophylaxie de souches des morpions
EP2116237A1 (fr) 2008-08-05 2009-11-11 Polichem SA Compositions pour traiter la rosacée comprenants du chitosane et un acide dicarboxylique
JP2011063541A (ja) * 2009-09-17 2011-03-31 Tokyo Institute Of Technology L−アルギニン結合因子の精製方法及びl−アルギニン様化合物のスクリーニング方法
EP2329849B1 (fr) 2009-11-18 2015-04-29 Galderma Research & Development Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN106038476B (zh) 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
AU2011231544B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
EP2629757A2 (fr) 2010-10-21 2013-08-28 Galderma S.A. Compositions de gel de brimonidine et leurs procédés d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631776A1 (fr) * 1993-07-02 1995-01-04 Roussel Uclaf Utilisation de dérivés de la bêta-naphtoquinone pour l'accélération de la prolifération des cellules endothéliales et de l'inhibition des no synthases
WO1995024884A1 (fr) * 1994-03-16 1995-09-21 Handelman, Joseph, H. Inhibition de la croissance pileuse
WO1996026711A1 (fr) * 1995-02-27 1996-09-06 L'oreal Inhibiteurs de no-synthase
WO1997015280A1 (fr) * 1995-10-26 1997-05-01 L'oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2744915A1 (fr) * 1996-02-16 1997-08-22 Oreal Composition cosmetique a base de cellules indifferenciees de ginkgo biloba

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0631776A1 (fr) * 1993-07-02 1995-01-04 Roussel Uclaf Utilisation de dérivés de la bêta-naphtoquinone pour l'accélération de la prolifération des cellules endothéliales et de l'inhibition des no synthases
WO1995024884A1 (fr) * 1994-03-16 1995-09-21 Handelman, Joseph, H. Inhibition de la croissance pileuse
WO1996026711A1 (fr) * 1995-02-27 1996-09-06 L'oreal Inhibiteurs de no-synthase
WO1997015280A1 (fr) * 1995-10-26 1997-05-01 L'oreal Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
FR2744915A1 (fr) * 1996-02-16 1997-08-22 Oreal Composition cosmetique a base de cellules indifferenciees de ginkgo biloba

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.A.QURESHI ET AL.: "From Bedside to the Bench and Back", ARCH. DERMATOL., vol. 132, no. 8, August 1996 (1996-08-01), pages 889 - 903, XP002075669 *
G.SAUERMANN ET AL.: "Influence of NO-Synthase Antagonists in Rosacea Patients", J.INVEST DERMATOL., vol. 108, no. 4, April 1997 (1997-04-01), pages 657, XP002075670 *
S.M.BIRNBAUM ET AL.: "Preparation of the Optical Isomers of Arginine, Histidine and S-Benzylcysteine by Asymmetric Enzymatic Hydrolysis of their Acetyl Derivatives", ARCH.BIOCHEM., vol. 39, 1952, pages 108 - 118, XP002075668 *

Also Published As

Publication number Publication date
WO1998036730A2 (fr) 1998-08-27
JP2001512471A (ja) 2001-08-21
EP0969790A2 (fr) 2000-01-12

Similar Documents

Publication Publication Date Title
WO1998036730A3 (fr) Compositions de traitement de l'acne rosacee
CA2267186A1 (fr) Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
WO2002072031A3 (fr) Composes de tetracycline substitue utilises en tant qu'antifongiques synergiques
WO2002047706A3 (fr) Inhibition sélective de la cox-2 au moyen d'extraits végétaux
WO1999004752A3 (fr) Procede pour le traitement de la pigmentation de la peau
WO1996021655A3 (fr) Inhibiteurs de la calpaine et/ou de la cathepsine b derives d'oxazolidine substituee
WO2000037107A3 (fr) Procede d'utilisation d'un inhibiteur de cyclooxygenase-2 et d'un inhibiteur de metalloproteinase matricielle en tant que therapie combinee dans le traitement de la neoplasie
WO2001015678A3 (fr) Utilisation topique d'agonistes des kappa opioides afin de traiter les douleurs oculaires
WO2001051043A3 (fr) Compositions et methodes de traitement de maladies neoplasiques au moyen de combinaisons de limonoides, de flavonoides et de tocotrienols
WO1999015167A3 (fr) Utilisation de limonoides et de flavonoides d'agrumes et de tocotrienols pour le traitement du cancer
WO2003053383A3 (fr) Utilisation cosmetique d’au moins une hydrophobine pour le traitement des matieres keratiniques
CA2257010A1 (fr) Methodes et compositions pour le traitement et la prevention des tumeurs, des troubles relies a des tumeurs et de la cachexie
WO1994004541A3 (fr) Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
ZA973487B (en) Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment.
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
WO2000009101A3 (fr) Utilisation de composes oestrogenes en tant qu'agents antifongiques
WO1997004788A3 (fr) Utilisation de glycosides de calendula dans le traitement du psoriasis
WO2000021513A3 (fr) Procedes pour traiter la sclerose en plaques
AU8853998A (en) Composition comprising vitamin k and vitamin d, for treating or preventing osteoporosis
AU2002232400A1 (en) Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
CA2275167A1 (fr) Utilisation locale d'agonistes opioides kappa dans le traitement de la douleur oculaire
WO1998022101A3 (fr) Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques
EP1171145A4 (fr) Utilisation de la catechine pour la prevention ou le traitement de la restenose coronarienne
MXPA00007394A (es) Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998913571

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 536269

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09367748

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998913571

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998913571

Country of ref document: EP